文献速递流行病学与生物统计临床试验与 GCP

癌症分期与死亡率作为癌症筛查随机临床试验终点的比较:系统综述与荟萃分析

Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA · 2024-01-01

该荟萃分析纳入41项在欧美和亚洲开展的癌症筛查随机临床试验,比较癌症特异性死亡率与III-IV期癌症发病率作为终点的相关性。结果显示,两者相关性因癌种而异,卵巢癌和肺癌相关性最高,乳腺癌中等,结直肠癌和前列腺癌较弱,提示晚期癌症发病率对部分癌种可作为癌症特异性死亡率的替代终点,但对另一些癌种不适用。

要点

  • 在癌症筛查随机临床试验中,晚期癌症发病率对部分癌种可能适合作为癌症特异性死亡率的替代终点,但对其他癌种不适用。
  • 卵巢癌和肺癌试验中,癌症特异性死亡率降低与III-IV期癌症发病率降低的相关性最高。
  • 乳腺癌相关性中等,结直肠癌和前列腺癌相关性弱。

核心结论

  • 在癌症筛查随机临床试验中,晚期癌症发病率对部分癌种可能是癌症特异性死亡率的合适替代终点,但对另一些癌种不适用。
  • 这些结果对多癌种筛查试验具有意义。

研究设计与样本

  • 该荟萃分析纳入41项在欧洲、北美和亚洲开展的癌症筛查随机临床试验,发表于2024年2月19日之前。
  • 提取的数据包括干预组和对照组中的参与者数量、癌症诊断数和癌症死亡数。
  • 对每项临床试验,计算干预组与对照组之间癌症特异性死亡率参与者数和III-IV期癌症发病率的百分比降低。
  • 纳入的随机临床试验测试了乳腺癌(n=6)、结直肠癌(n=11)、肺癌(n=12)、卵巢癌(n=4)、前列腺癌(n=4)和其他癌症(n=4)筛查的获益。

主要发现

  • 癌症特异性死亡率降低与III-IV期癌症发病率降低之间的相关性因癌种而异(I2=65%;P=.02)。
  • 卵巢癌试验相关性最高(Pearson ρ=0.99 [95%CI, 0.51-1.00]),肺癌试验次之(Pearson ρ=0.92 [95%CI, 0.72-0.98])。
  • 乳腺癌试验相关性中等(Pearson ρ=0.70 [95%CI, -0.26至0.96])。
  • 结直肠癌(Pearson ρ=0.39 [95%CI, -0.27至0.80])和前列腺癌(Pearson ρ=-0.69 [95%CI, -0.99至0.81])试验相关性弱。
  • 线性回归斜率估计为卵巢癌1.15、肺癌0.75、结直肠癌0.40、乳腺癌0.28、前列腺癌-3.58,提示给定幅度的III-IV期癌症发病率降低在不同癌种中产生不同幅度的癌症特异性死亡率变化(异质性P=.004)。

关键数值与推荐

  • 卵巢癌试验中,癌症特异性死亡率降低与III-IV期癌症发病率降低的Pearson相关系数为0.99(95%CI, 0.51-1.00)。
  • 肺癌试验中,癌症特异性死亡率降低与III-IV期癌症发病率降低的Pearson相关系数为0.92(95%CI, 0.72-0.98)。
  • 乳腺癌试验中,癌症特异性死亡率降低与III-IV期癌症发病率降低的Pearson相关系数为0.70(95%CI, -0.26至0.96)。
  • 结直肠癌试验中,癌症特异性死亡率降低与III-IV期癌症发病率降低的Pearson相关系数为0.39(95%CI, -0.27至0.80)。
  • 前列腺癌试验中,癌症特异性死亡率降低与III-IV期癌症发病率降低的Pearson相关系数为-0.69(95%CI, -0.99至0.81)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized clinical trials of cancer screening typically use cancer-specific mortality as the primary end point. The incidence of stage III-IV cancer is a potential alternative end point that may accelerate completion of randomized clinical trials of cancer screening. OBJECTIVE: To compare cancer-specific mortality with stage III-IV cancer as end points in randomized clinical trials of cancer screening. DESIGN, SETTING, AND PARTICIPANTS: This meta-analysis included 41 randomized clinical trials of cancer screening conducted in Europe, North America, and Asia published through February 19, 2024. Data extracted included numbers of participants, cancer diagnoses, and cancer deaths in the intervention and comparison groups. For each clinical trial, the effect of screening was calculated as the percentage reduction between the intervention and comparison groups in the incidence of participants with cancer-specific mortality and stage III-IV cancer. EXPOSURES: Randomization to a cancer screening test or to a comparison group in a clinical trial of cancer screening. MAIN OUTCOMES AND MEASURES: End points of cancer-specific mortality and incidence of stage III-IV cancer were compared using Pearson correlation coefficients with 95% CIs, linear regression, and fixed-effects meta-analysis. RESULTS: The included randomized clinical trials tested benefits of screening for breast (n = 6), colorectal (n = 11), lung (n = 12), ovarian (n = 4), prostate (n = 4), and other cancers (n = 4). Correlation between reductions in cancer-specific mortality and stage III-IV cancer varied by cancer type (I2 = 65%; P = .02). Correlation was highest for trials that screened for ovarian (Pearson ρ = 0.99 [95% CI, 0.51-1.00]) and lung (Pearson ρ = 0.92 [95% CI, 0.72-0.98]) cancers, moderate for breast cancer (Pearson ρ = 0.70 [95% CI, -0.26 to 0.96]), and weak for colorectal (Pearson ρ = 0.39 [95% CI, -0.27 to 0.80]) and prostate (Pearson ρ = -0.69 [95% CI, -0.99 to 0.81]) cancers. Slopes from linear regression were estimated as 1.15 for ovarian cancer, 0.75 for lung cancer, 0.40 for colorectal cancer, 0.28 for breast cancer, and -3.58 for prostate cancer, suggesting that a given magnitude of reduction in incidence of stage III-IV cancer produced different magnitudes of change in incidence of cancer-specific mortality (P for heterogeneity = .004). CONCLUSIONS AND RELEVANCE: In randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types, but is not suitable for others. These results have implications for clinical trials of multicancer screening tests.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Feng X, Zahed H, Onwuka J, et al. Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis. JAMA. 2024. PMID: 38583868. doi:10.1001/jama.2024.5814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。